{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:25:21Z","timestamp":1787505921381,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","cysticfibrosisjournal.com","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jcf.2024.06.002","type":"journal-article","created":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T12:47:31Z","timestamp":1717850851000},"page":"72-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["ETD001: A novel inhaled ENaC blocker with an extended duration of action in vivo"],"prefix":"10.1016","volume":"24","author":[{"given":"Henry","family":"Danahay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schofield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Charlton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0236-2027","authenticated-orcid":false,"given":"Sarah","family":"Lilley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Sabater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Salathe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5341-6785","authenticated-orcid":false,"given":"Nathalie","family":"Baumlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P","family":"Collingwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gosling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jcf.2024.06.002_bib0001","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2796.2006.01744.x","article-title":"Evidence for airway surface dehydration as the initiating event in CF airway disease","volume":"261","author":"Boucher","year":"2007","journal-title":"J Intern Med"},{"issue":"5","key":"10.1016\/j.jcf.2024.06.002_bib0002","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/clinchem\/35.5.726","article-title":"Defective epithelial ion transport in cystic fibrosis","volume":"35","author":"Quinton","year":"1989","journal-title":"Clin Chem"},{"issue":"5","key":"10.1016\/j.jcf.2024.06.002_bib0003","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/apa.15155","article-title":"Cystic fibrosis in the year 2020: a disease with a new face","volume":"109","author":"De Boeck","year":"2020","journal-title":"Acta Paediatr"},{"issue":"3","key":"10.1016\/j.jcf.2024.06.002_bib0004","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1152\/physrev.00007.2002","article-title":"Epithelial sodium channel\/degenerin family of ion channels: a variety of functions for a shared structure","volume":"82","author":"Kellenberger","year":"2002","journal-title":"Physiol Rev"},{"issue":"25","key":"10.1016\/j.jcf.2024.06.002_bib0005","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJM198112173052502","article-title":"Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis","volume":"305","author":"Knowles","year":"1981","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jcf.2024.06.002_bib0006","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1056\/NEJM199907153410304","article-title":"Pulmonary epithelial sodium-channel dysfunction and excess airway liquid in pseudohypoaldosteronism","volume":"341","author":"Kerem","year":"1999","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jcf.2024.06.002_bib0007","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1164\/ajrccm\/141.3.605","article-title":"Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy","volume":"141","author":"App","year":"1990","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jcf.2024.06.002_bib0008","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.coph.2018.09.007","article-title":"The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis","volume":"43","author":"Shei","year":"2018","journal-title":"Curr Opin Pharmacol"},{"issue":"6","key":"10.1016\/j.jcf.2024.06.002_bib0009","article-title":"ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies","volume":"56","year":"2020","journal-title":"Mall, MA. Eur Respir J"},{"issue":"4","key":"10.1016\/j.jcf.2024.06.002_bib0010","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0002-9343(00)00496-4","article-title":"Drug-induced hyperkalemia: old culprits and new offenders","volume":"109","author":"Perazella","year":"2000","journal-title":"Am J Med"},{"key":"10.1016\/j.jcf.2024.06.002_bib0011","unstructured":"www.Clinicaltrials.gov A study to evaluate the safety and efficacy of VX-371 in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. ClinicalTrials.gov Identifier: NCT02709109."},{"issue":"4","key":"10.1016\/j.jcf.2024.06.002_bib0012","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jcf.2022.02.010","article-title":"AZD5634, an inhaled ENaC inhibitor, in healthy subjects and patients with cystic fibrosis","author":"Kristensson","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2024.06.002_bib0013","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00746-2021","article-title":"Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study","volume":"59","author":"Goss","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2024.06.002_bib0014","unstructured":"www.Clinicaltrials.gov Safety, pharmacokinetics and pharmacodynamics study of inhaled QBW276 in patients with cystic fibrosis. ClinicalTrials.gov Identifier: NCT02566044."},{"issue":"11","key":"10.1016\/j.jcf.2024.06.002_bib0015","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1111\/bph.13075","article-title":"NVP-QBE170: an inhaled blocker of the epithelial sodium channel with a reduced potential to induce hyperkalaemia","volume":"172","author":"Coote","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jcf.2024.06.002_bib0016","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1111\/j.1476-5381.2010.00872.x","article-title":"Animal research: reporting in vivo experiments: the ARRIVE guidelines","volume":"160","author":"Kilkenny","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jcf.2024.06.002_bib0017","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1111\/j.1476-5381.2010.00873.x","article-title":"Guidelines for reporting experiments involving animals: the ARRIVE guidelines","volume":"160","author":"McGrath","year":"2010","journal-title":"Br J Pharmacol"},{"issue":"8","key":"10.1016\/j.jcf.2024.06.002_bib0018","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1164\/rccm.201908-1641OC","article-title":"TMEM16A potentiation: a novel therapeutic approach for the treatment of cystic fibrosis","volume":"201","author":"Danahay","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.jcf.2024.06.002_bib0019","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1089\/jamp.2017.1384","article-title":"In vitro characterization of the eflow closed system nebulizer with glycopyrrolate inhalation solution","volume":"31","author":"Pham","year":"2018","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"4","key":"10.1016\/j.jcf.2024.06.002_bib0020","first-page":"763","article-title":"Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique","volume":"3","author":"Brand","year":"2008","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.jcf.2024.06.002_bib0021","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejps.2016.01.005","article-title":"Effects of ramp-up of inspired airflow on in vitro aerosol dose delivery performance for certain dry powder inhalers","volume":"84","author":"Ung","year":"2016","journal-title":"Eur J Pharm Sci"},{"issue":"S96","key":"10.1016\/j.jcf.2024.06.002_bib0022","article-title":"Tolerance of ETD001, a long-acting inhaled epithelial sodium channel blocker, in humans","volume":"21","author":"Russell","year":"2022","journal-title":"J Cystic Fibrosis"},{"issue":"24","key":"10.1016\/j.jcf.2024.06.002_bib0023","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122695","article-title":"Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTR","volume":"3","author":"Donaldson","year":"2018","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.jcf.2024.06.002_bib0024","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa043900","article-title":"A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis","volume":"354","author":"Elkins","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jcf.2024.06.002_bib0025","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1124\/jpet.107.130443","volume":"325","author":"Hirsh","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"issue":"S28","key":"10.1016\/j.jcf.2024.06.002_bib0026","first-page":"218","article-title":"Safety, pharmacokinetics and effects on mucus clearance following administration of 552-02 to normal healthy volunteers","volume":"40","author":"Donaldson","year":"2005","journal-title":"Pediatr Pulmonol."},{"issue":"3","key":"10.1016\/j.jcf.2024.06.002_bib0027","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa043891","article-title":"Mucus clearance and lung function in cystic fibrosis with hypertonic saline","volume":"354","author":"Donaldson","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jcf.2024.06.002_bib0028","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1152\/jappl.1999.87.6.2191","article-title":"Aerosolization of P2Y(2)-receptor agonists enhances mucociliary clearance in sheep","volume":"87","author":"Sabater","year":"1999","journal-title":"J Appl Physiol"},{"issue":"2","key":"10.1016\/j.jcf.2024.06.002_bib0029","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1164\/ajrccm.164.2.2008094","article-title":"Effect of aerosolized uridine 5\u2032-triphosphate on mucociliary clearance in mild chronic bronchitis","volume":"164","author":"Bennett","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"S45","key":"10.1016\/j.jcf.2024.06.002_bib0030","first-page":"P79","article-title":"Brevenal is comparable to aerosol ivacaftor in reversing the slowed mucus transport induced by airway challenge with CFTRInh-172 alone or in combination with human neutrophil elastase in sheep","volume":"51","author":"Abraham","year":"2016","journal-title":"Pediatric Pulm"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932400081X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932400081X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T17:11:02Z","timestamp":1738257062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156919932400081X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S156919932400081X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.06.002","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ETD001: A novel inhaled ENaC blocker with an extended duration of action in vivo","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}